ANRO (Alto Neuroscience) Total Liabilities: $32.89 Mil (As of Mar. 2026)


ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $27.04
! 2 Warning Signs
View Full Analysis

What is Alto Neuroscience Total Liabilities?

Alto Neuroscience ANRO +6.88% 12 Total Liabilities is $32.89 Mil as of Mar. 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Alto Neuroscience's Total Liabilities for the quarter that ended in Mar. 2026 was $32.89 Mil.

Alto Neuroscience's quarterly Total Liabilities declined from Sep. 2025 ($35.45 Mil) to Dec. 2025 ($33.55 Mil) and declined from Dec. 2025 ($33.55 Mil) to Mar. 2026 ($32.89 Mil).

Alto Neuroscience's annual Total Liabilities declined from Dec. 2023 ($158.30 Mil) to Dec. 2024 ($26.08 Mil) but then increased from Dec. 2024 ($26.08 Mil) to Dec. 2025 ($33.55 Mil).

Alto Neuroscience Total Liabilities Historical Data

* Premium members only.

The historical data trend for Alto Neuroscience's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alto Neuroscience Total Liabilities Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
41.27 89.26 158.30 26.08 33.55

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.82 34.47 35.45 33.55 32.89
ANRO
12GF Score
Alto Neuroscience Inc ANRO
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alto Neuroscience Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alto Neuroscience's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.325+(22.222+-3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=33.55

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=184.689-151.142
=33.55

Alto Neuroscience's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.115+(19.775+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=32.89

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=276.259-243.369
=32.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $32.89 Mil mean?
Alto Neuroscience (ANRO) has a Total Liabilities of $32.89 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alto Neuroscience and its competitors.
Is Alto Neuroscience's Total Liabilities too high?
Alto Neuroscience's current Total Liabilities is $32.89 Mil. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Total Liabilities compare to MRVI and BBOT?
Alto Neuroscience's Total Liabilities of $32.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alto Neuroscience and its competitors. Alto Neuroscience's current Total Liabilities is $32.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Total Liabilities of $32.89 Mil. The current Total Liabilities is $32.89 Mil. Alto Neuroscience's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Total Liabilities is $32.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.04
Price